Last reviewed · How we verify
paricalcitol capsule
Paricalcitol is a selective vitamin D receptor agonist that activates the vitamin D receptor to regulate calcium and phosphorus metabolism and suppress parathyroid hormone secretion.
Paricalcitol is a selective vitamin D receptor agonist that activates the vitamin D receptor to regulate calcium and phosphorus metabolism and suppress parathyroid hormone secretion. Used for Secondary hyperparathyroidism in patients with chronic kidney disease on hemodialysis, Secondary hyperparathyroidism in patients with chronic kidney disease stages 3-4 (non-dialysis dependent).
At a glance
| Generic name | paricalcitol capsule |
|---|---|
| Also known as | ABT-358, paricalcitol, Zemplar |
| Sponsor | Abbott |
| Drug class | Vitamin D receptor agonist |
| Target | Vitamin D receptor (VDR) |
| Modality | Small molecule |
| Therapeutic area | Nephrology / Endocrinology |
| Phase | FDA-approved |
Mechanism of action
Paricalcitol binds to and activates the vitamin D receptor (VDR), a nuclear receptor that regulates calcium homeostasis, phosphorus metabolism, and parathyroid hormone (PTH) suppression. By selectively targeting VDR in the parathyroid glands and other tissues, it reduces PTH levels and helps normalize serum calcium and phosphorus in patients with secondary hyperparathyroidism. This selective activation profile is designed to minimize hypercalcemia and hyperphosphatemia compared to calcitriol.
Approved indications
- Secondary hyperparathyroidism in patients with chronic kidney disease on hemodialysis
- Secondary hyperparathyroidism in patients with chronic kidney disease stages 3-4 (non-dialysis dependent)
Common side effects
- Hypercalcemia
- Hyperphosphatemia
- Elevated calcium-phosphorus product
- Nausea
- Vomiting
Key clinical trials
- A PiLot ClinicaL TrIal of ParicAlcitol for ChroNiC PancrEatitis (EARLY_PHASE1)
- Paricalcitol Improves Anemia of Inflammation (PHASE4)
- Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D Insufficiency (PHASE4)
- A Study to Assess the Efficacy and Safety of Paricalcitol in the Treatment of Chronic Kidney Disease With Secondary Hyperparathyroidism (PHASE3)
- Identification of Markers for Determining the Efficacy of Vitamin D Receptor Activator Therapy in Stage 3/4 CKD Patients
- Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic Rickets (PHASE3)
- Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation. (PHASE4)
- Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- paricalcitol capsule CI brief — competitive landscape report
- paricalcitol capsule updates RSS · CI watch RSS
- Abbott portfolio CI